Clinical Trials Logo

Clinical Trial Summary

This is a prospective, observational study designed to contribute data from patients with symptomatic metastatic bone disease treated at Sibley Memorial Hospital and Johns Hopkins Medicine to an international registry hosted by the Swedish Regional Cancer Centrum in Stockholm, Sweden. This protocol supports a worldwide effort to collect and store information from patients treated for symptomatic bone metastases within the International Skeletal Metastasis Registry (ISMR)


Clinical Trial Description

The registry is designed to update a suite of clinical decision-support tools designed for use when treating patients with metastatic bone disease. The models estimate the likelihood of survival at 1, 3, 6, 12, 18, and 24 months post surgery, which in turn, may be used for surgical decision-making. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05058014
Study type Observational [Patient Registry]
Source Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contact Jacqueline Quivers
Phone 202-243-2294
Email [email protected]
Status Recruiting
Phase
Start date August 16, 2018
Completion date August 16, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04634227 - Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot) Early Phase 1
Completed NCT04660591 - Length of the Femoral Stem in Arthroplasty Done for Patients With Proximal Femoral Metastatic Lesion N/A
Not yet recruiting NCT04364724 - CTFEA Myeloma Study
Terminated NCT03468075 - Gemcitabine Plus Ascorbate for Sarcoma in Adults Phase 2
Active, not recruiting NCT03963531 - Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)